Evidence map›Paper›PMID 40976901›Full record

ArticleCurrent cancer drug targets2026

Multi-omics Approaches to CCAAT/Enhancer-Binding Protein Beta in Oral Squamous Cell Carcinoma: Crosstalk Between Tumor Cells and Tumor-Associated Macrophages Driving Disease Progression.

Min Li, Jilun Liu, Wenjuan Zhang, Ruonan Sun, Wenjing Wang, Xin Liu, Linyu Jin, Yongle Qiu

Abstract read
PubMed Publisher
In one paragraph

Article in Current cancer drug targets, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Min LiDepartment of Prosthodontics, Handan Stomatology Hospital, Handan, Hebei, 056000, P.R. China.
Jilun LiuDepartment of Oral Surgery, The Second Hospital of Hebei Medical University, Shijiazhuang, Hebei, 050000, P.R. China.
Wenjuan ZhangDepartment of Oral Surgery, The Second Hospital of Hebei Medical University, Shijiazhuang, Hebei, 050000, P.R. China.
Ruonan SunDepartment of Stomatology, Second Hospital of Shijiazhuang, Shijiazhuang, Hebei, 050000, P.R. China.
Wenjing WangDepartment of Stomatology, The Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei, 050000, P.R. China.
Xin LiuDepartment of Stomatology, The Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei, 050000, P.R. China.
Linyu JinDepartment of Stomatology, The Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei, 050000, P.R. China.
Yongle QiuDepartment of Stomatology, The Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei, 050000, P.R. China.ORCID 0000-0002-5118-815X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundCCAAT/Enhancer-Binding Protein Beta (CEBPB) is an important transcription factor that regulates tumor progression. However, the mechanism by which CEBPB regulates the progression of Oral Squamous Cell Carcinoma (OSCC) remains incompletely understood. Tumor progression depends on complex intercellular interactions within the tumor microenvironment. The purpose of this study was to investigate the role and epigenetic regulatory mechanisms of CEBPB in interactions between OSCC cells and tumor-infiltrating immune cells.

methodsBulk RNA-seq, ChIP-seq, and scRNA-seq data were obtained from The Cancer Genome Atlas (TCGA) database and the Gene Expression Omnibus (GEO) database. The HOMER algorithm was employed to identify enhancers and predict the CEBPB-binding motif. Cell cluster analysis, functional enrichment, and intercellular interaction analysis were performed using the "Seurat" R package. H3K27ac enrichment at GAS6 enhancers was validated by ChIP-qPCR. Metastatic OSCC cells with CEBPB knockdown or GAS6 overexpression were established and co-cultured with THP-1 cells. IL-10 and IL-6 secretion from co-cultured THP-1 cells was detected via ELISA. Chemotaxis of OSCC cells toward THP-1 cells was assessed through a Transwell assay.

resultsCEBPB was upregulated in OSCC and correlated with poor prognosis. By integrating H3K27ac ChIP-seq and bulk RNA-seq data, 131 CEBPB-regulated enhancer-controlled genes were identified in lymph node metastatic OSCC cells. scRNA-seq analysis revealed eight major cell clusters in primary foci and lymph node metastases, including T/NK cells, malignant epithelial cells, B/plasma cells, macrophages, fibroblasts, dendritic cells, endothelial cells, and mast cells, with the malignant epithelial cells stratified into distinct sub-clusters. CEBPB expression was elevated in malignant epithelial cells of lymph node metastases compared to primary foci. Furthermore, 15 pairs of enhanced ligand-receptor interactions were identified in lymph node metastases relative to primary foci. GAS6 was a CEBPB-regulated enhancer-controlled gene, primarily mediating interactions between malignant cells and macrophages. CEBPB knockdown in metastatic OSCC cells significantly impaired their chemotaxis toward cocultured THP-1 cells, and downregulated IL-10/IL-6 secretion and CD206 expression in cocultured THP-1 cells. Conversely, GAS6 overexpression reversed these inhibitory effects.

conclusionCEBPB activated GAS6 transcription in metastatic OSCC cells. The CEBPB/ GAS6 axis in metastatic OSCC cells enhanced their chemotaxis toward macrophages and promoted the M2 polarization of macrophages, thereby facilitating the establishment of an immunosuppressive microenvironment.

Indexed as

Carcinoma, Squamous CellCCAAT-Enhancer-Binding Protein-betaMouth NeoplasmsSquamous Cell Carcinoma of Head and NeckTumor-Associated MacrophagesCell Line, TumorDisease ProgressionGene Expression Regulation, NeoplasticHumansMultiomicsTumor MicroenvironmentCCAAT-Enhancer-Binding Protein-betaCEBPB protein, humanCCAAT/enhancer-binding protein betaenhancerGAS6intercellular interactionmacrophageOral squamous cell carcinoma

Identifiers

PMID40976901

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.